Possible involvement of the sigma‐1 receptor chaperone in chemotherapeutic‐induced neuropathic pain

Previous studies have shown that ligands of the sigma‐1 receptor chaperone (Sig‐1R) regulate pain‐related behaviors. Clinical use of chemotherapeutics is often compromised due to their adverse side effects, particularly those related to neuropathy. Previous studies have shown that repeated administration of oxaliplatin and paclitaxel produces neuropathy in rodents. Therefore, the aim of the present study was to clarify the involvement of the Sig‐1R in chemotherapeutic‐induced neuropathy by examining the effects of oxaliplatin and paclitaxel on the Sig‐1R levels in the spinal cord, and by examining the effects of Sig‐1R agonist and antagonist on oxaliplatin‐ and paclitaxel‐induced neuropathy in rats. Chemotherapeutic‐induced neuropathic pain was accompanied by a significant reduction of the Sig‐1R level in the spinal cord. Furthermore, the administration of paclitaxel to CHO cells that stably overexpressed Sig‐1Rs induced the clustering of Sig‐1Rs. We also found that the Sig‐1R agonist SA4503 potently inhibited the neuropathy induced by oxaliplatin‐ and paclitaxel, whereas this action was abolished by the Sig‐1R antagonist NE‐100. These results suggest that the reduction of Sig‐1R activity is involved in chemotherapeutic‐induced neuropathy, and the Sig‐1R agonist SA4503 could serve as a potential candidate for the treatment of chemotherapeutic‐induced neuropathy. Synapse 69:526–532, 2015 . © 2015 Wiley Periodicals, Inc.